ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0523

Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies

Fabian Proft1, Désirée van der Heijde2, Xenofon Baraliakos3, Joerg Ermann4, Carmen Fleurinck5, Ute Massow6, Natasha De Peyrecave7, Vanessa Taieb8, Astrid van Tubergen9 and Victoria Navarro-Compán10, 1Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 4Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5UCB Pharma, Oosterzele, Belgium, 6UCB Pharma, Monheim am Rhein, Germany, 7UCB Pharma, Brussels, Belgium, 8UCB Pharma, Colombes, France, 9Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, Netherlands, 10Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain

Meeting: ACR Convergence 2023

Keywords: clinical trial, Outcome measures, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0510–0542) Spondyloarthritis Including Psoriatic Arthritis – Treatment: AxSpA Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic rheumatic disease which requires optimal management and disease control. Patients (pts) can experience loss of response in the long term and maintenance of response is an internationally recommended treatment target.1

Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL‑17F in addition to IL‑17A, has demonstrated sustained clinical efficacy to Week (Wk) 52 in pts across the full disease spectrum of axSpA in the phase 3 studies BE MOBILE 1 and 2.2

Here, we report the maintenance of stringent clinical responses through 1 year of treatment with BKZ in pts with non‑radiographic axSpA (nr-axSpA) and radiographic-axSpA (r‑axSpA, i.e., AS).3

Methods: In BE MOBILE 1 (NCT03928704; nr-axSpA; pts met ASAS criteria for axSpA) and BE MOBILE 2 (NCT03928743; r‑axSpA; pts fulfilled ASAS and modified New York criteria for r-axSpA), pts were randomized to receive subcutaneous BKZ 160mg every 4 wks (Q4W) or placebo (PBO) to Wk 16. From Wks 16−52, all pts received BKZ 160mg Q4W.4,5

Assessment of SpondyloArthritis international Society ≥40% improvement (ASAS40) and Ankylosing Spondylitis Disease Activity Score (ASDAS) < 2.1 (low disease activity [LDA]) or < 1.3 (inactive disease [ID]) responses to Wk 52 were assessed among BKZ‑randomized pts who responded at Wk 16. Non-responder imputation (NRI), and multiple imputation (MI) were used for missing ASAS40 and ASDAS data, respectively. Observed case (OC) data and Wk 16 and Wk 52 responder rates for all BKZ-randomized pts (NRI or MI) are also reported.

The number of treatment-emergent adverse events (TEAEs) to Wk 52 are reported for pts who received ≥1 dose of BKZ.

Results: A total of 128 and 221 pts were randomized to BKZ 160mg Q4W in BE MOBILE 1 and 2, respectively. At Wk 16, 47.7% and 44.8% of these pts achieved the primary endpoint, ASAS40, and this increased to 60.9% and 58.4% at Wk 52 (NRI, Figure). Of pts that achieved ASAS40 at Wk 16, 82.0% and 83.8% maintained this response at Wk 52 (NRI, Figure).

ASDAS LDA was achieved by 46.1% and 44.8% of BKZ-randomized pts at Wk 16 of BE MOBILE 1 and 2, respectively; this increased to 61.6% and 57.1% at Wk 52 (MI, Figure). Of pts that achieved ASDAS LDA at Wk 16, 88.9% and 88.4% maintained this response at Wk 52 (MI, Figure).

At Wk 16 of BE MOBILE 1 and 2, ASDAS ID was achieved by 18.8% and 16.4% of BKZ‑randomized pts, respectively; and this increased to 25.2% and 23.4% at Wk 52 (MI). Among Wk 16 ASDAS ID responders, ASDAS ID was maintained by 79.2% and 75.1% at Wk 24, 85.3% and 71.7% at Wk 36, and 88.0% and 58.7% at Wk 52 (MI).

To Wk 52 of BE MOBILE 1 and 2, 183/244 (75.0%) and 249/330 (75.5%) pts reported ≥1 TEAE whilst receiving BKZ, respectively; 9 (3.7%) and 20 (6.1%) reported serious TEAEs.

Conclusion: Dual inhibition of IL-17F and IL-17A with BKZ provided robust maintenance of stringent clinical responses from Wk 16 to Wk 52 across the full disease spectrum of axSpA.

References:1. Smolen J. Ann Rheum Dis 2018;77:3–17; 2. Baraliakos X. Arthritis Rheumatol 2022;74 (suppl 9); 3. Boel A. Ann Rheum Dis 2019;78:1545–9; 4. Deodhar A. Ann Rheum Dis 2022;81:772–3; 5. van der Heijde D. Ann Rheum Dis 2022;81:12–3.

Supporting image 1

Figure. Maintenance of ASAS40 and ASDAS LDA (ASDAS <2.1) through 52 weeks of BKZ 160 mg Q4W among Week 16 ASAS40 and ASDAS LDA responders, respectively, from BE MOBILE 1 and 2


Disclosures: F. Proft: AbbVie, 2, 6, Amgen, 2, 6, BMS, 2, 6, Celgene, 2, 6, Eli Lilly, 5, Hexal, 2, 6, Janssen, 2, 6, MSD, 2, 6, Novartis, 2, 5, 6, Pfizer, 2, 6, Roche, 2, 6, UCB Pharma, 2, 5, 6; D. van der Heijde: AbbVie, 2, Bayer, 2, BMS, 2, Eli Lilly, 2, Galapagos, 2, Gilead, 2, GSK, 2, Imaging Rheumatology BV, 12, Director, Janssen, 2, Novartis, 2, Pfizer, 2, Takeda, 2, UCB Pharma, 2; X. Baraliakos: AbbVie, 2, 6, BMS, 2, 6, Chugai, 2, 6, Eli Lilly, 2, 6, Galapagos, 2, 6, Gilead, 2, 6, MSD, 2, 6, Novartis, 2, 6, Pfizer Inc, 2, 6, UCB, 2, 6; J. Ermann: AbbVie, 2, 5, Boehringer Ingelheim, 5, Janssen, 2, Novartis, 2, 5, Pfizer, 2, 5, Takeda, 2, UCB Pharma, 2; C. Fleurinck: UCB Pharma, 3; U. Massow: UCB Pharma, 3; N. De Peyrecave: UCB Pharma, 3; V. Taieb: UCB Pharma, 3, 11; A. van Tubergen: MSD, 5, Novartis, 2, 5, Pfizer, 2, 5, 6, UCB Pharma, 2, 5; V. Navarro-Compán: AbbVie, 2, 5, 6, Eli Lilly, 2, 6, Galapagos, 2, Janssen, 6, MoonLake, 2, MSD, 2, 6, Novartis, 2, 5, 6, Pfizer, 2, 6, UCB, 2, 6.

To cite this abstract in AMA style:

Proft F, van der Heijde D, Baraliakos X, Ermann J, Fleurinck C, Massow U, De Peyrecave N, Taieb V, van Tubergen A, Navarro-Compán V. Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/bimekizumab-maintained-stringent-clinical-responses-through-week-52-in-patients-with-axial-spondyloarthritis-results-from-two-phase-3-studies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/bimekizumab-maintained-stringent-clinical-responses-through-week-52-in-patients-with-axial-spondyloarthritis-results-from-two-phase-3-studies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology